Goldberg, S. B., & Herbst, R. S. (2018). Should chemotherapy plus immune checkpoint inhibition be the standard front-line therapy for metastatic NSCLC? Cancer.
Citação norma ChicagoGoldberg, Sarah B., and Roy S. Herbst. "Should Chemotherapy Plus Immune Checkpoint Inhibition Be the Standard Front-line Therapy for Metastatic NSCLC?" Cancer 2018.
MLA CitationGoldberg, Sarah B., and Roy S. Herbst. "Should Chemotherapy Plus Immune Checkpoint Inhibition Be the Standard Front-line Therapy for Metastatic NSCLC?" Cancer 2018.
Advarsel: Disse citationer er muligvist ikke 100% nøjagtige.